
JCR Pharmaceuticals Launches Phase III Trial of JR-142, Long-Acting Growth Hormone Therapy
JCR Pharmaceuticals Co., Ltd. (TSE 4552) today announced the dosing of the first patient in its Phase III clinical trial of JR-142 (INN: redalsomatropin alfa) in Japan. This marks a…











